Aspira Women's Health Inc. (AWH)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations
Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations. Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses.
Aspira (AWH) Reports Q3 Loss, Lags Revenue Estimates
Aspira (AWH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.48 per share a year ago.
Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript
Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Nicole Sandford - Chief Executive Officer & Director Sandy Milligan - President John Kallassy - Interim Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Incorporated Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Aspira Women's Health Inc. (AWH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aspira Women's Health Inc. ever had a stock split?
Aspira Women's Health Inc. Profile
| Professional Services Industry | Industrials Sector | Nicolette Possemato CEO | NASDAQ (CM) Exchange | 04537Y208 CUSIP |
| US Country | 66 Employees | - Last Dividend | 4 Mar 2008 Last Split | - IPO Date |
Overview
Aspira Women's Health Inc., along with its subsidiaries, is at the forefront of discovering, developing, and commercializing noninvasive AI-powered diagnostic tests for gynecologic diseases within the United States. Initially established as Vermillion, Inc. in 1993, the company underwent a rebranding to Aspira Women's Health Inc. in June 2020 and is headquartered in Austin, Texas. With a strong commitment to innovation in women's health, Aspira Women's Health has formed strategic alliances with leading institutions and companies, including Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, Medical University of Lodz, and Quest Diagnostics, Incorporated. These collaborations aim to advance research and improve the diagnostic capabilities for gynecologic conditions. Aspira Women's Health operates Aspira Labs, a dedicated laboratory focusing on the application of biomarker-based technologies to manage gynecologic cancers and diseases more effectively. Their national sales force and platform, Aspira Synergy, alongside a marketing and distribution agreement with BioReference Health, LLC, significantly extend the distribution of their innovative products.
Products and Services
- Ova1Plus
A qualitative serum test designed to assess the likelihood of malignancy in women presenting with an ovarian adnexal mass. Ova1Plus stands as a flagship product, utilizing advanced analytical methods to offer critical insights that aid in clinical decision-making.
- Overa
A biomarker test that aims to maintain the high sensitivity seen in Ova1Plus. Overa serves as an essential tool in the ongoing assessment of ovarian malignancy risks, highlighting Aspira Women's Health's commitment to continuous improvement and precision in diagnostics.
- OvaWatch
A laboratory-developed test designed to assist in the clinical assessment of malignancy risk among women thought to have an indeterminate or benign adnexal mass. OvaWatch represents a significant stride forward in noninvasive diagnostic approaches, providing peace of mind and clearer direction for further medical evaluation.
- OvaMDx
This multi-marker test combines serum proteins, clinical data, and miRNA to assess the risk of ovarian cancer in women with an adnexal mass. OvaMDx exemplifies the integration of multi-omic data to refine risk assessment and personalize patient care strategies.
- EndoCheck
A protein biomarker test designed specifically to identify ovarian endometriomas. EndoCheck addresses a critical gap in the early detection of endometriomas, facilitating timely and appropriate interventions for affected women.
- EndoMDx
Targeted at the identification of endometriosis, EndoMDx utilizes cutting-edge diagnostic technologies to unveil this challenging and often underdiagnosed condition. This development underscores Aspira Women's Health's dedication to bringing novel solutions to complex gynecologic diseases.
